Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD metabolism

  • Matalonga, Jonathan
  • Glaria, Estibaliz
  • Bresque, Marina
  • Escande, Carlos
  • Carbó, José María
  • Kiefer, Kerstin
  • Vicente, Ruben
  • León, Theresa E.
  • Beceiro, Susana
  • Pascual-García, Mónica
  • Serret, Joan
  • Sanjurjo, Lucía
  • Morón-Ros, Samantha
  • Riera, Antoni
  • Paytubi, Sonia
  • Juárez, Antonio
  • Sotillo, fernando
  • Lindbom, Lennart
  • Caelles, Carme
  • Sarrias, María Rosa
  • Sancho, Jaime
  • Castrillo, Antonio
  • Chini, Eduardo N.
  • Valledor, Annabel F.
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of non-opsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bone-marrow-derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway., This work was supported by grants from the Spanish MICINN to A.F.V. (SAF2010-14989, SAF2011-23402, and SAF2014-57856), R.V. (SAF2010-16725), and the NuRCaMeIn network (SAF2015-71878-REDT); from Fundació la Marató de TV3 to A.F.V. (080930) and R.V. (20134030); and from COST Action BM1404 (Mye-EUNITER). M.R.S. is a Miguel Servet II researcher (ISCIII CPII14/00021), and C.E. is supported by a grant from ANII (INNOVA II, FCE_1_2014_1_104002, Uruguay). J.M. received fellowships from the Spanish MICINN (FPI, BES-2009-014828) and from the Institut Pasteur-Pierre Ledoux Jeunesse Internationale Foundation, M.P. received fellowships from the Spanish MEC (FPU, AP 2007-00821), J.M.C. received fellowships from the UB (APIF), and M.B. received fellowships from ANII (Uruguay)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The nuclear receptor LXR modulates interleukin-18 levels in macrophages through multiple mechanisms

  • Pourcet, Benoit
  • Castrillo, Antonio
  • Valledor, Annabel F.
  • Pineda-Torra, Inés
Pourcet, B. et al., IL-18 is a member of the IL-1 family involved in innate immunity and inflammation. Deregulated levels of IL-18 are involved in the pathogenesis of multiple disorders including inflammatory and metabolic diseases, yet relatively little is known regarding its regulation. Liver X receptors or LXRs are key modulators of macrophage cholesterol homeostasis and immune responses. Here we show that LXR ligands negatively regulate LPS-induced mRNA and protein expression of IL-18 in bone marrow-derived macrophages. Consistent with this being an LXR-mediated process, inhibition is abolished in the presence of a specific LXR antagonist and in LXR-deficient macrophages. Additionally, IL-18 processing of its precursor inactive form to its bioactive state is inhibited by LXR through negative regulation of both pro-caspase 1 expression and activation. Finally, LXR ligands further modulate IL-18 levels by inducing the expression of IL-18BP, a potent endogenous inhibitor of IL-18. This regulation occurs via the transcription factor IRF8, thus identifying IL-18BP as a novel LXR and IRF8 target gene. In conclusion, LXR activation inhibits IL-18 production through regulation of its transcription and maturation into an active pro-inflammatory cytokine. This novel regulation of IL-18 by LXR could be applied to modulate the severity of IL-18 driven metabolic and inflammatory disorders., This work was supported by a Medical Research Council New Investigator Grant G0801278 (IPT), British Heart Foundation Project Grant PG/13/10/30000 (IPT), and Ministerio de Economia y Competitividad (MINECO) Grant SAF2014-56819-R (AC) and SAF2014-57856 (AFV)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacologic activation of LXR alters the expression profile of tumor-associated macrophages and the abundance of regulatory T cells in the tumor microenvironment

  • Carbó, José María
  • León, Theresa E.
  • Font-Díaz, Joan
  • Rosa, Juan V. de la
  • Castrillo, Antonio
  • Picard, Felix R.
  • Staudenraus, Daniel
  • Huber, Magdalena
  • Cedó, Lídia
  • Escolà-Gil, Joan Carles
  • Campos, Lucía
  • Bakiri, Latifa
  • Wagner, Erwin F.
  • Caelles, Carme
  • Stratmann, Thomas
  • Ginderachter, Jo A. Van
  • Valledor, Annabel F.
Liver X receptors (LXR) are transcription factors from the nuclear receptor family that are activated by oxysterols and synthetic high-affinity agonists. In this study, we assessed the antitumor effects of synthetic LXR agonist TO901317 in a murine model of syngeneic Lewis Lung carcinoma. Treatment with TO901317 inhibited tumor growth in wild-type, but not in LXR-deficient mice, indicating that the antitumor effects of the agonist depends on functional LXR activity in host cells. Pharmacologic activation of the LXR pathway reduced the intratumoral abundance of regulatory T cells (Treg) and the expression of the Treg-attracting chemokine Ccl17 by MHCIIhigh tumor-associated macrophages (TAM). Moreover, gene expression profiling indicated a broad negative impact of the LXR agonist on other mechanisms used by TAM for the maintenance of an immunosuppressive environment. In studies exploring the macrophage response to GM-CSF or IL4, activated LXR repressed IRF4 expression, resulting in subsequent downregulation of IRF4-dependent genes including Ccl17. Taken together, this work reveals the combined actions of the LXR pathway in the control of TAM responses that contribute to the antitumoral effects of pharmacologic LXR activation. Moreover, these data provide new insights for the development of novel therapeutic options for the treatment of cancer., This work was supported by the following grants: Spanish Ministry of Economy and Competitivity (MINECO) grants SAF2017-89510-R and SAF2014-57856-P [to A.F. Valledor and C. Caelles; SAF2014-56819-R to A. Castrillo; SAF2017-90604-REDT and SAF2015-71878-REDT to the NuRCaMeIn network (to A.F. Valledor, C. Caelles, and A. Castrillo); Spanish Ministry of Science and Innovation (MICINN) grants SAF2011-23402 and SAF2010-14989 (to A.F. Valledor); Fundacio La Marato de TV3 grant 080930 (to A.F. Valledor); grants DFG HU 1824/5-1, 1824/7-1, and 1824/9-1 (to M. Huber); the European Cooperation in Science and Technology (COST) Action BM1404 Mye-EUNITER (http://www.mye-euniter. eu/; to A.F. Valledor, J.A. Van Ginderachter); and Instituto de Salud Carlos III and FEDER “Una manera de hacer Europa” grant FIS 16/00139 (to J.C. Escola-Gil). CIBERDEM is an Instituto de Salud Carlos III project. J.M. C received a fellowship from the University of Barcelona (APIF) and J. Font-Díaz received a fellowship from the Spanish Ministry of Science, Innovation and Universities (FPI, PRE2018-085579).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism

  • Matalonga, Jonathan
  • Glaria, Estibaliz
  • Bresque, Mariana|||0000-0002-4570-3629
  • Escande, Carlos|||0000-0002-9611-0903
  • Carbó, José María|||0000-0001-8301-5360
  • Kiefer, Kerstin
  • Vicente, Ruben
  • León, Theresa E.
  • Beceiro, Susana
  • Pascual-García, Mónica|||0000-0002-9768-0641
  • Serret, Joan
  • Sanjurjo, Lucía|||0000-0003-4006-8010
  • Morón-Ros, Samantha|||0000-0002-6205-2442
  • Riera, Antoni|||0000-0001-7142-7675
  • Paytubi, Sonia
  • Antonio Juarez, Antonio
  • Sotillo, Fernando
  • Lindbom, Lennart
  • Caelles, Carme
  • Sarrias, Maria-Rosa|||0000-0001-6929-8069
  • Sancho, Jaime
  • Castrillo, Antonio|||0000-0002-2057-2159
  • Chini, Eduardo N.
  • Valledor, Annabel F.|||0000-0003-4232-2633
Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages.remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.